Table 2 Correlations between miR-199b expression and clinicopathologic factors in DGC and IGC.
From: miR-199a and miR-199b facilitate diffuse gastric cancer progression by targeting Frizzled-6
miR-199b (DGC) | P-value | miR-199b (IGC) | P-value | |||
|---|---|---|---|---|---|---|
High (n = 46) | low (n = 249) | High (n = 8) | low (n = 104) | |||
Age | 0.633 | 1 | ||||
> 65 | 20 (43.5) | 121 (48.6) | 5 (62.5) | 59 (56.7) | ||
≤ 65 | 26 (56.5) | 128 (51.4) | 3 (37.5) | 45 (43.3) | ||
Sex | 1 | 1 | ||||
Male | 33 (71.7) | 181 (72.7) | 5 (62.5) | 71 (68.3) | ||
Female | 13 (28.3) | 68 (27.0) | 3 (37.5) | 33 (31.7) | ||
Location | 0.956 | 0.254 | ||||
Upper | 8 (17.4) | 46 (18.5) | 2 (25.0) | 8 (7.7) | ||
Mid | 6 (13.0) | 29 (11.7) | 1 (12.5) | 17 (16.3) | ||
Lower | 32 (69.6) | 173 (69.8) | 5 (62.5) | 79 (76.0) | ||
Lymphovascular invasion | 0.095 | 0.460 | ||||
Present | 24 (52.2) | 94 (37.8) | 5 (62.5) | 44 (42.3) | ||
Absent | 22 (47.8) | 155 (62.2) | 3 (37.5) | 60 (57.7) | ||
MMR | 1 | 1 | ||||
Deficiency | 2 (4.3) | 11 (4.4) | 1 (12.5) | 7 (6.7) | ||
Intact | 44 (95.7) | 238 (95.6) | 7 (87.5) | 97 (93.3) | ||
EBV | 1 | 1 | ||||
Positive | 2 (6.4) | 8 (3.2) | 0 (0) | 14 (13.5) | ||
Negative | 44 (93.6) | 241 (96.8) | 8 (100) | 90 (86.5) | ||
T stage | < 0.001* | 1 | ||||
1a and 1b (EGC) | 8 (17.4) | 118 (47.4) | 3 (37.5) | 45 (43.3) | ||
2, 3 and 4 (AGC) | 38 (82.6) | 131 (52.6) | 5 (62.5) | 59 (56.7) | ||
Lymph node metastasis | 0.003* | 0.873 | ||||
Present | 28 (60.9) | 91 (36.5) | 4 (50.0) | 42 (40.4) | ||
Absent | 18 (39.1) | 158 (63.5) | 4 (50.0) | 62 (59.6) | ||
